+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Allogeneic Cell Therapy Market - Distribution by Type of Cell Therapy, Source of Cell, Target Indication, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Report

  • 205 Pages
  • July 2023
  • Region: Global
  • Roots Analysis
  • ID: 5852471

The global allogeneic cell therapy market is estimated to be worth USD 0.9 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 14% during the forecast period 2023-2035. Allogeneic cell therapies refer to off-the-shelf therapies that are isolated from donor tissues (such as cord blood and bone marrow), processed ex vivo in the labs and then administered into patients / cryopreserved in a cell bank. Since these therapies are manufactured in advance, they are readily available and eliminate the need for individualized production for every patient. Owing to their various benefits, such as improved and consistent product quality (due to rigorous quality control measures taken during processing), reduced cost (due to centralized manufacturing process) and flexibility in approaching the same donor or choosing a different donor (in case the patient requires another course of the treatment), allogeneic cell therapies have gained significant traction in the healthcare industry. Further, recent advancements in gene editing technologies, such as CRISPR / Cas9, have opened up new possibilities for allogeneic cell therapies by enabling precise genetic modifications in the donor cells in order to enhance their therapeutic properties and reduce the risk of immune rejection.

Over the past few years, a number of allogeneic cell therapies targeting a myriad of disorders, including hematological malignancies (such as multiple myeloma, leukemia), post-transplant lymphoproliferative disorders (PTLD), neurological disorders, musculoskeletal disorders and autoimmune / inflammatory disorders, have received approval from various regulatory authorities, globally. In December 2022, the European Commission approved the first allogeneic T-cell therapy, namely Ebvallo, (developed by Atara Biotherapeutics) for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease. In addition, the FDA approved an allogenic mesenchymal stem cell therapy, Osteocel® Plus (developed by NuVasive), for the treatment of degenerative disc disease. Driven by the continuous efforts of both industry and non-industry players, rising prevalence of chronic diseases and non-malignant disorders, and challenges associated with production of autologous cell therapies, the global allogeneic cell therapies market is likely to witness substantial market growth during the forecast period.

Key Market Insights

The  Allogeneic Cell Therapy Market, 2023-2035 - Distribution by Type of Cell Therapy (Virus-Specific T-Cell, Stem Cell and Regulatory T-Cell), Source of Cell (Peripheral Blood, Bone Marrow, Umbilical Cord Blood, Adipose Tissue and Placenta), Target Indication (Bone Disorder, Critical Limb Ischemia, Crohn’s Disease, Diabetic Foot Ulcer, Graft versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndrome, Cytomegalovirus Infection, Others), Therapeutic Area (Oncological Disorders, Neurological Disorders, Musculoskeletal Disorders, Autoimmune / Inflammatory Disorders and Post-Transplant Infections), and Key Geographical Regions (North America,  Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts market report features an extensive study of the current market landscape, market size and future opportunities for the allogenic cell therapy developers, during the given forecast period. Further, the report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the allogeneic therapy market report are briefly discussed below. 

Allogeneic Cell Therapy vs Autologous Cell Therapy

Allogeneic cell therapy and autologous cell therapy are two distinct approaches in regenerative medicine market. In autologous cell therapy, the cells are derived from the patient's own body, processed ex-vivo and reintroduced into the same patient; this personalized approach ensures compatibility and minimizes the risk of immune rejection. However, these therapies require a longer production time, as each patient's cells need to be individually processed. On the other hand, allogeneic cell therapy involves the use of cells from a healthy donor; these collected donor cells might be given directly to a genetically similar patient or added to a cell bank. Allogeneic cell therapy has various advantages, including immediate accessibility, scalability and cost-effectiveness, however, it may involve the risk of immune rejection. 

Pipeline Analysis: Competitive Landscape of Allogeneic Cell Therapy 

Allogenic cell therapy market landscape features the presence of close to 195 large, mid-sized and small companies developing allogeneic cell therapies, for a wide range of indications. It is worth highlighting that over 470 allogenic cell therapies are currently being evaluated in different preclinical / clinical stages, either as monotherapies or in combination with other drugs. In April 2023, Gamida Cell received approval from the FDA for its umbilical cord blood-derived, allogeneic stem cell therapy, Omisirge® (omidubicel-onlv); the therapy is used to treat patients with hematologic malignancies. The growing demand for novel allogeneic cell therapies, approvals from various regulatory bodies and continuous advancements in cell therapy manufacturing process, are expected to drive the allogeneic cell therapies market growth during the forecast period.

Clinical Trials Analysis: More than 365 Trials are Evaluating Allogeneic Cell Therapies to Treat Various Hematologic Malignancies and Solid Tumors

Over the years, companies involved in the development of allogeneic cell therapies have made significant efforts to conduct clinical trials for evaluating the efficacy of allogeneic cell therapies, for the treatment of various disorders, including infectious diseases (adenovirus infection,  coronavirus infection and cytomegalovirus infection), neurological disorders (autism, bipolar depression, Parkinson’s disease, stroke) and oncological disorders (acute myeloid leukemia, biliary tract cancer, breast cancer and multiple myeloma). Over 365 clinical trials have been registered across different geographical regions to evaluate various allogenic cell therapies. Of these trials, majority (~180) were registered in North America and maximum number of patients (9,300) were observed to be enrolled in clinical trials conducted in North America, accounting for about 55% of the overall enrollment. It is worth mentioning that Fundamenta Therapeutics is conducting the maximum number of trials in this industry for different types of cancers, such as acute lymphoblastic leukemia, acute lymphoblastic lymphoma and non-Hodgkin’s lymphoma. In addition, an allogeneic CAR T cell therapy, ALLO-715 (developed by Allogene) for the treatment of relapsed / refractory multiple myeloma has demonstrated positive results in the Phase I clinical trials.

Market Trends Analysis: Partnerships and Collaborations have Fueled Allogenic Cell Therapy Market Growth

Several stakeholders have been forging alliances with other industry / non-industry players for the development of allogeneic cell therapies. It is worth highlighting that, since 2019, over 90 strategic partnerships have been established in the allogeneic cell therapy market. Majority of such deals are focused on research and development, product / technology licensing, and development and commercialization of allogenic cell therapies. In March 2023, Tessa Therapeutics entered into a research and development agreement with US National Cancer Institute for Tessa’s allogeneic CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy, TT11X, useful in the treatment of non-Hodgkin’s lymphoma. In January 2022, Allogene Therapeutics signed a licensing agreement with Antion Biosciences for the latter company’s miRNA technology (miCAR™) in order to advance multiplex gene silencing tool (useful in the development of innovative allogeneic CAR T cell therapy). 

Market Trends Analysis: Increase in Funding Reflect the Rising Interest in Allogenic Cell Therapy Market

The growing interest in allogeneic cell therapy market can be validated by the fact that in the past four years, close to USD 8.8 billion has been invested by several investors based across the globe, in companies engaged in the development of allogeneic cell therapies. It is worth noting that, majority of the funds have been raised through venture rounds. In terms of the funding amount raised, Legend Biotech raised the maximum funding amount (USD 487.3 million) through initial public offering. In December 2022, Gamida Cell announced the closing of a convertible term loan of USD 25 million with Highbridge Capital Management; the funding is planned to be used to advance the company’s allogeneic NK cell therapy pipeline. 

Market Analysis: Global Allogeneic Cell Therapies Market Size

The global allogeneic cell therapy market is estimated to be worth USD 900 million in 2023. Driven by the increasing need for novel allogenic cell therapies, along with growing development pipeline and encouraging clinical trial results, the allogenic cell therapies market is anticipated to grow at a CAGR of 14% during the forecast period. Specifically, in terms of target disease indication, the market is anticipated to be driven by allogeneic cell therapies being developed for the treatment of lymphoma and leukemia. 

Regional Analysis: North America to Hold the Largest Allogeneic Cell Therapy Market Share

Majority of the companies developing allogeneic cell therapies are headquartered in North America, followed by companies based in Asia Pacific. Consequently, more than 60% of the global market of allogeneic cell therapies is anticipated to be captured by players based in North America, in 2035.  The factors responsible for the growth of the allogeneic cell therapy market in North America include the rising incidence of acute as well as chronic disorders, increasing FDA approvals for novel allogenic cell therapies and growing adoption of innovative therapies in the developed countries. In addition, the US government has been actively involved in providing reimbursement for expensive allogeneic cell therapies, recognizing their potential to revolutionize healthcare and improve patient outcomes.

Leading Allogeneic Cell Therapy Companies

Examples of the key allogeneic cell therapy companies (based on number of products under development; the complete list of players is available in the full report) include Artiva Biotherapeutics, Allogene Therapeutics, Atara Biotherapeutics, Cellenkos, Cell2Cure, Celularity, Cellular Biomedicine Group, CHABiotech, CRISPR Therapeutics, Fate Therapeutics, Fundamenta Therapeutics, GC Cell, Hope Biosciences, Immunity Bio, Mesoblast, Nanjing Bioheng Biotech, Orca Bio, Pluristem Therapeutics, Poseida Therapeutics and Stemedica Cell Technologies. This market report also includes an easily searchable excel database of all the allogeneic therapy companies (developers) worldwide.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in the allogenic cell therapy market, across different segments.

The research report presents an in-depth analysis, highlighting the capabilities of various stakeholders in this market, across different geographies. Amongst other elements, the market report includes:

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of allogeneic cell therapy market and its likely evolution in the mid-long term.
  • A general overview of allogeneic cell therapy, along with information on their manufacturing process, key advantages, challenges and recent developments within this market.
  • A detailed assessment of the overall landscape of allogeneic cell therapies, based on several relevant parameters, such as year of establishment, company size (in terms of employee count), location of headquarters, phase of development (preclinical, clinical and marketed), route of administration (intravenous, intraarticular, topical, intramuscular, intrathecal, subretinal, intracoronary, inhalational and others), type of cell therapy (stem cell therapies, T-cell therapies, NK cell therapies, dendritic cell therapies and others), source of cell (peripheral blood, umbilical cord, bone marrow and placenta), dosing frequency (single dose and multiple dose), type of therapy (monotherapies and combination therapies), target patient segment (children, adults and elderly patients), target indication (acute myeloid leukemia, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, B-cell lymphoma, COVID-19, osteoarthritis, acute respiratory distress syndrome, myelodysplastic syndrome, colorectal cancer and gastric cancer), and therapeutic area (oncological disorders, neurological disorders, musculoskeletal disorders, infectious diseases, autoimmune / inflammatory disorders, post-transplant infections, cardiovascular disorders, respiratory disorders, cerebrovascular disorders, ophthalmic disorders, dermatological disorders, genetic disorders, kidney disorders, liver disorders, metabolic disorders and others). 
  • A detailed analysis of the partnerships established between stakeholders engaged in this industry, since 2019, covering research and development agreements, product / technology licensing agreements, product development and commercialization agreements, manufacturing / supply agreements, product development agreements, clinical trial agreements, mergers, acquisitions, product commercialization agreements and other relevant agreements.
  • An analysis of the funding and investments that have been made into companies developing allogeneic cell therapies, which include venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing. It includes a detailed analysis of the funding instances that have taken place during the period 2019 to 2023, highlighting the growing interest of venture capital (VC) community and other strategic investors in this market.
  • An analysis of completed and ongoing clinical trials related to allogeneic cell therapies, based on several relevant parameters, such as trial registration year, trial status, trial phase, study design, type of sponsor, geography, and most active industry and non-industry players (in terms of number of trials).
  • An insightful analysis, highlighting the key opinion leaders (KOLs) investigating clinical trials related to allogeneic cell therapies, based on several relevant parameters, such as type of KOL, qualification, type of organization, affiliated organization, geographical location of KOLs and target disease indication. In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.

One of the key objectives of this market report was to estimate the current market size, opportunity and the future growth potential of the allogeneic cell therapies market, over the forecast period. We have provided informed estimates on the likely evolution of the market for the forecast period, 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of cell therapy (virus-specific T-cell, stem cell and regulatory T-cell), source of cell (peripheral blood, bone marrow, umbilical cord blood, adipose tissue and placenta), target indication (Bone Disorder, Critical Limb Ischemia, Crohn’s Disease, Diabetic Foot Ulcer, Graft versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndrome, Cytomegalovirus Infection, Others), therapeutic area (oncological disorders, neurological disorders, musculoskeletal disorders, autoimmune / inflammatory disorders, post-transplant infections), and key geographical regions (North America,  Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with some of the key industry stakeholders.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified. 

Frequently Asked Questions

Question 1: What is allogeneic cell therapy?

Answer: Allogeneic cell therapy involves the isolation of cells from a donor, followed by ex vivo manipulation and subsequent administration into the patients.

Question 2: What is allogenic vs autologous cell therapy?

Answer: Allogenic cell therapy refers to a cellular therapy in which the cells from a healthy donor are used to treat a patient while autologous cell therapy refers to a cellular therapy in which the cells are used from the patient’s peripheral blood.

Question 3: What are the advantages of allogeneic cell therapy?

Answer: Allogeneic cell therapy has various advantages, including availability as a scalable off-the-shelf product, diversity of cells or tissues, higher quality product, cost effectiveness and easy automation.

Question 4: What is an example of autologous cell therapy?

Answer: An example of autologous cell therapy is Epicel (developed by Genzyme Biosurgery) for the treatment of deep dermal or full thickness burns.

Question 5: Which are the most common sources from which allogeneic cells can be derived?

Answer: Allogeneic cell therapies can be derived through different sources, such as adipose tissue, amniotic sac, bone marrow, cord blood, peripheral blood and placenta.

Question 6: How many companies are developing allogeneic cell therapies?

Answer: At present, close to 195 companies claim to develop allogeneic cell therapies for different therapeutic areas. The majority of allogeneic cell therapies are stem cell therapies, followed by T-cell therapies (including CAR T cell, gamma delta T cell, virus-specific T cell, regulatory T cell, TCR and TIL).

Question 7: What are the partnership trends in the allogeneic cell therapies domain?

Answer: Research and development, product / technology licensing agreements, product development agreements, are the most common types of partnerships inked by stakeholders in this industry.

Question 8: How big is the global allogeneic cell therapies market?

Answer: The global market for allogeneic cell therapies is anticipated to be worth USD 0.9 billion in 2023.

Question 9: What is the likely growth rate (CAGR) of allogeneic cell therapy market?

Answer: The global allogeneic cell therapy market is expected to grow at a CAGR of 14% during the forecast period 2023 to 2035.

Question 10: Which region captures the largest market share of the allogeneic cell therapy market?

Answer: At present, the allogeneic cell therapies market is dominated by North America, capturing more than 60% of the overall market size.

Question 11: Which segment is likely to have the largest market share in the allogeneic cell therapy market?

Answer: Currently, the oncological disorders segment dominates the allogeneic cell therapy market.

Table of Contents

1. PREFACE
1.1. Allogeneic Cell Therapy Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Allogeneic Cell Therapy
3.2. Manufacturing Process of Allogeneic Cell Therapy
3.3. Advantages Offered by Allogeneic Cell Therapy
3.4. Challenges Associated with Allogeneic Cell Therapy
3.5. Recent Developments in Allogeneic Cell Therapy Industry
3.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Allogeneic Cell Therapies: Market Landscape
4.1.1. Analysis by Phase of Development
4.1.2. Analysis by Route of Administration
4.1.3. Analysis by Type of Cell Therapy
4.1.4. Analysis by Source of Cell
4.1.5. Analysis by Dosing Frequency
4.1.6. Analysis by Type of Therapy
4.1.7. Analysis by Target Patient Segment
4.1.8. Analysis by Target Indication
4.1.9. Analysis by Therapeutic Area
4.2. Allogeneic Cell Therapies: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Most Active Players: Analysis by Number of Therapies

5. PARTNERSHIPS AND COLLABORATIONS
5.1. Chapter Overview
5.2. Partnership Models
5.2. Allogeneic Cell Therapies: Partnerships and Collaborations
5.2.1 Analysis by Year of Partnership
5.2.2. Analysis by Type of Partnership
5.2.3. Analysis by Year and Type of Partnership
5.2.4. Analysis by Type of Cell Therapy
5.2.5. Analysis by Therapeutic Area
5.2.6. Analysis by Type of Partner
5.2.7. Most Active Players: Analysis by Number of Partnerships
5.2.8. Analysis by Geography
5.2.8.1. Intercontinental and Intracontinental Deals
5.2.8.2. Local and International Deals

6. FUNDING AND INVESTMENTS
6.1. Chapter Overview
6.2. Types of Funding
6.3. Allogeneic Cell Therapies: Funding and Investments
6.3.1. Analysis by Year of Investment
6.3.2. Analysis by Amount Invested
6.3.3. Analysis by Type of Funding
6.3.4. Analysis of Amount Invested by Type of Funding
6.3.5. Analysis of Amount Invested by Year and Type of Funding
6.3.6. Analysis by Type of Investor
6.3.7. Analysis by Type of Therapy
6.3.8. Analysis by Geography
6.3.9. Leading Investors: Analysis by Number of Instances
6.3.10. Most Active Players: Analysis by Number of Instances
6.3.11. Most Active Players: Analysis by Amount Invested

7. CLINICAL TRIAL ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Allogeneic Cell Therapies: Clinical Trial Analysis
7.2.1. Analysis by Trial Registration Year
7.2.2. Analysis by Trial Status
7.2.3. Analysis by Trial Registration Year and Trial Status
7.2.4. Analysis by Trial Registration Year and Patients Enrolled
7.2.5. Analysis by Trial Status and Patients Enrolled
7.2.6. Analysis by Trial Phase
7.2.7. Analysis by Study Design
7.2.8. Analysis by Trial Status, Trial Phase and Geography
7.2.9. Analysis by Type of Sponsor
7.2.10. Most Active Industry Players: Analysis by Number of Trials
7.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
7.2.12. Analysis by Geography

8. KEY OPINION LEADERS
8.1. Methodology and Key Parameters
8.2. Allogeneic Cell Therapies: Key Opinion Leaders (KOLs)
8.2.1. Analysis by Type of KOL
8.2.2. Analysis by Qualification
8.2.3. Analysis by Type of Organization
8.2.4. Analysis by Affiliated Organization
8.2.5. Analysis by Target Disease Indication
8.2.6. Analysis by Geographical Location of KOLs
8.2.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
8.2.8 Most Prominent KOLs: Peer Group 2 (Study Directors)
8.2.9 Most Prominent KOLs: Peer Group 3 (Study Chair)
8.2.10. Most Prominent KOLs: Analysis by RA Score
8.2.11. Most Prominent KOLs: Comparison of RA Score and Third-Party Score
8.2.12. Concluding Remarks

9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Allogeneic Cell Therapy Market, 2023-2035
9.3.1. Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035
9.3.1.1. Allogeneic Cell Therapy Market for Regulatory T-Cell, 2023-2035
9.3.1.2. Allogeneic Cell Therapy Market for Stem Cell, 2023-2035
9.3.1.3. Allogeneic Cell Therapy Market for Virus-Specific T-Cell, 2023-2035
9.3.2. Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035
9.3.2.1. Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies, 2023-2035
9.3.2.2. Allogeneic Cell Therapy Market for Bone Marrow-derived Therapies, 2023-2035
9.3.3.3. Allogeneic Cell Therapy Market for Umbilical Cord Blood-derived Therapies, 2023-2035
9.3.3.4. Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies, 2023-2035
9.3.3.5. Allogeneic Cell Therapy Market for Placenta-derived Therapies, 2023-2035
9.3.3. Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035
9.3.3.1. Allogeneic Cell Therapy Market for Bone Disorder, 2023-2035
9.3.3.2. Allogeneic Cell Therapy Market for Critical Limb Ischemia, 2023-2035
9.3.3.3. Allogeneic Cell Therapy Market for Crohn’s Disease 2023-2035
9.3.3.4. Allogeneic Cell Therapy Market for Diabetic Foot Ulcer, 2023-2035
9.3.3.5. Allogeneic Cell Therapy Market for Graft versus Host Disease, 2023-2035
9.3.3.6. Allogeneic Cell Therapy Market for Leukemia, 2023-2035
9.3.3.7. Allogeneic Cell Therapy Market for Lymphoma, 2023-2035
9.3.3.8. Allogeneic Cell Therapy Market for Myelodysplastic Syndrome, 2023-2035
9.3.3.9. Allogeneic Cell Therapy Market for Cytomegalovirus Infection, 2023-2035
9.3.3.10. Allogeneic Cell Therapy Market for Others, 2023-2035
9.3.4. Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035
9.3.4.1. Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders, 2023-2035
9.3.4.2. Allogeneic Cell Therapy Market for Musculoskeletal Disorders, 2023-2035
9.3.4.3. Allogeneic Cell Therapy Market for Neurological Disorders, 2023-2035
9.3.4.4. Allogeneic Cell Therapy Market for Oncological Disorders, 2023-2035
9.3.4.5. Allogeneic Cell Therapy Market for Post-Transplant Infection, 2023-2035
9.3.5. Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035
9.3.5.1. Allogeneic Cell Therapy Market in North America, 2023-2035
9.3.5.1.1. Allogeneic Cell Therapy Market in the US, 2023-2035
9.3.5.1.2. Allogeneic Cell Therapy Market in Canada, 2023-2035
9.3.5.2. Allogeneic Cell Therapy Market in Europe, 2023-2035
9.3.5.2.1. Allogeneic Cell Therapy Market in Germany, 2023-2035
9.3.5.2.2. Allogeneic Cell Therapy Market in the UK, 2023-2035
9.3.5.2.3. Allogeneic Cell Therapy Market in France, 2023-2035
9.3.5.2.4. Allogeneic Cell Therapy Market in Italy, 2023-2035
9.3.5.2.5. Allogeneic Cell Therapy Market in Spain, 2023-2035
9.3.5.3. Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World, 2023-2035
9.3.5.3.1. Allogeneic Cell Therapy Market in China, 2023-2035
9.3.5.3.2. Allogeneic Cell Therapy Market in Australia, 2023-2035
9.3.5.3.3. Allogeneic Cell Therapy Market in Japan, 2023-2035
9.4. Allogeneic Cell Therapy Market: Product-wise Sales Forecast, 2023-2035
9.4.1. AB-205 / E-CEL cells
9.4.1.1. Sales Forecast (USD Billion)
9.4.1.2. Net Present Value (USD Billion)
9.4.1.3. Value Creation Analysis
9.4.2. allo-APZ2-OTS
9.4.2.1. Sales Forecast (USD Billion)
9.4.2.2. Net Present Value (USD Billion 9.4.2.3. Value Creation Analysis
9.4.3. ALLO-ASC-DFU
9.4.3.1. Sales Forecast (USD Billion)
9.4.3.2. Net Present Value (USD Billion)
9.4.3.3. Value Creation Analysis
9.4.4. CAP-1002
9.4.4.1. Sales Forecast (USD Billion)
9.4.4.2. Net Present Value (USD Billion)
9.4.4.3. Value Creation Analysis
9.4.5. CARTISTEM®
9.4.5.1. Sales Forecast (USD Billion)
9.4.5.2. Net Present Value (USD Billion)
9.4.5.3. Value Creation Analysis
9.4.6. Cx601
9.4.6.1. Sales Forecast (USD Billion)
9.4.6.2. Net Present Value (USD Billion)
9.4.6.3. Value Creation Analysis
9.4.7. CYP-004
9.4.7.1. Sales Forecast (USD Billion)
9.4.7.2. Net Present Value (USD Billion)
9.4.7.3. Value Creation Analysis
9.4.8. Cytovir CMV T cells
9.4.8.1. Sales Forecast (USD Billion)
9.4.8.2. Net Present Value (USD Billion)
9.4.8.3. Value Creation Analysis
9.4.9. Darvadstrocel / Cx601
9.4.9.1. Sales Forecast (USD Billion)
9.4.9.2. Net Present Value (USD Billion)
9.4.9.3. Value Creation Analysis
9.4.10. ELIXCYTE
9.4.10.1. Sales Forecast (USD Billion)
9.4.10.2. Net Present Value (USD Billion)
9.4.10.3. Value Creation Analysis
9.4.11. Grafix®
9.4.11.1. Sales Forecast (USD Billion)
9.4.11.2. Net Present Value (USD Billion)
9.4.11.3. Value Creation Analysis
9.4.12. iCell CTL
9.4.12.1. Sales Forecast (USD Billion)
9.4.12.2. Net Present Value (USD Billion)
9.4.12.3. Value Creation Analysis
9.4.13. MDR-101
9.4.13.1. Sales Forecast (USD Billion)
9.4.13.2. Net Present Value (USD Billion)
9.4.13.3. Value Creation Analysis
9.4.14. MPC-06-ID / Rexlemestrocel-L
9.4.14.1. Sales Forecast (USD Billion)
9.4.14.2. Net Present Value (USD Billion)
9.4.14.3. Value Creation Analysis
9.4.15. MPC-25-Osteo
9.4.15.1. Sales Forecast (USD Billion)
9.4.15.2. Net Present Value (USD Billion)
9.4.15.3. Value Creation Analysis
9.4.16. MultiStem®
9.4.16.1. Sales Forecast (USD Billion)
9.4.16.2. Net Present Value (USD Billion)
9.4.16.3. Value Creation Analysis
9.4.17. NiCord® / Omidubicel
9.4.17.1. Sales Forecast (USD Billion)
9.4.17.2. Net Present Value (USD Billion)
9.4.17.3. Value Creation Analysis
9.4.18. Orca-T
9.4.18.1. Sales Forecast (USD Billion)
9.4.18.2. Net Present Value (USD Billion)
9.4.18.3. Value Creation Analysis
9.4.19. Osteocel® Plus
9.4.19.1. Sales Forecast (USD Billion)
9.4.19.2. Net Present Value (USD Billion)
9.4.19.3. Value Creation Analysis
9.4.20. PLX-PAD
9.4.20.1. Sales Forecast (USD Billion)
9.4.20.2. Net Present Value (USD Billion)
9.4.20.3. Value Creation Analysis
9.4.21. Revascor / MPC-150-IM / Rexlemestrocel-L
9.4.21.1. Sales Forecast (USD Billion)
9.4.21.2. Net Present Value (USD Billion)
9.4.21.3. Value Creation Analysis
9.4.22. Stempeucel®
9.4.22.1. Sales Forecast (USD Billion)
9.4.22.2. Net Present Value (USD Billion)
9.4.22.3. Value Creation Analysis
9.4.23. Tab-cel® / tabelecleucel
9.4.23.1. Sales Forecast (USD Billion)
9.4.23.2. Net Present Value (USD Billion)
9.4.23.3. Value Creation Analysis
9.4.24. TEMCELL® HS
9.4.24.1. Sales Forecast (USD Billion)
9.4.24.2. Net Present Value (USD Billion)
9.4.24.3. Value Creation Analysis
9.4.25. Trinity ELITE
9.4.25.1. Sales Forecast (USD Billion)
9.4.25.2. Net Present Value (USD Billion)
9.4.25.3. Value Creation Analysis
9.4.26. Trinity Evolution
9.4.26.1. Sales Forecast (USD Billion)
9.4.26.2. Net Present Value (USD Billion)
9.4.26.3. Value Creation Analysis
9.4.27. Viralym-M / Posoleucel
9.4.27.1. Sales Forecast (USD Billion)
9.4.27.2. Net Present Value (USD Billion)
9.4.27.3. Value Creation Analysis

10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Mesoblast
10.2.1 Company Snapshot
10.2.2. Interview Transcript: Eric Rose (Chief Medical Officer)
10.3. Triumvira Immunologics
10.3.1. Company Snapshot
10.3.2. Interview Transcript: Andreas Bader (Chief Scientific Officer)

11. APPENDIX I: TABULATED DATA12. APPENDIX I1: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 2.1 Executive Summary: Overall Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Funding and Investment Analysis
Figure 2.4 Executive Summary: Clinical Trial Analysis
Figure 2.5 Executive Summary: Key Opinion Leaders
Figure 2.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Manufacturing Process of Allogeneic Cell Therapy
Figure 3.2 Advantages Offered by Allogeneic Cell Therapy
Figure 3.3 Challenges Associated with Allogeneic Cell Therapy
Figure 4.1 Allogeneic Cell Therapies: Distribution by Phase of Development
Figure 4.2 Allogeneic Cell Therapies: Distribution by Route of Administration
Figure 4.3 Allogeneic Cell Therapies: Distribution by Type of Cell Therapy
Figure 4.4 Allogeneic Cell Therapies: Distribution by Source of Cell
Figure 4.5 Allogeneic Cell Therapies: Distribution by Dosing Frequency
Figure 4.6 Allogeneic Cell Therapies: Distribution by Type of Therapy
Figure 4.7 Allogeneic Cell Therapies: Distribution by Target Patient Segment
Figure 4.8 Allogeneic Cell Therapies: Distribution by Target Indication
Figure 4.9 Allogeneic Cell Therapies: Distribution by Therapeutic Area
Figure 4.10 Allogeneic Cell Therapies Developers: Distribution by Year of Establishment
Figure 4.11 Allogeneic Cell Therapies Developers: Distribution by Company Size
Figure 4.12 Allogeneic Cell Therapies Developers: Distribution by Location of Headquarters
Figure 4.13 Most Active Players: Distribution by Number of Therapies
Figure 5.1 Partnerships and Collaborations: Distribution by Year of Partnership, 2019-2023
Figure 5.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 5.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 5.4 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Figure 5.5 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 5.6 Partnerships and Collaborations: Distribution by Type of Partner
Figure 5.7 Most Active Players: Distribution by Number of Partnerships
Figure 5.8 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 5.9 Partnerships and Collaborations: Local and International Deals
Figure 6.1 Funding and Investments: Distribution by Year of Investment, 2019-2023
Figure 6.2 Funding and Investments: Distribution by Amount Invested (USD Million)
Figure 6.3 Funding and Investments: Distribution by Type of Funding
Figure 6.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 6.5 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Figure 6.6 Funding and Investments: Distribution by Type of Investor
Figure 6.7 Funding and Investments: Distribution by Type of Therapy
Figure 6.8 Funding and Investments: Distribution by Geography (Region-wise)
Figure 6.9 Funding and Investments: Distribution by Geography (Country-wise)
Figure 6.10 Leading Investors: Distribution by Number of Instances
Figure 6.11 Most Active Players: Distribution by Number of Instances
Figure 6.12 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
Figure 7.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Figure 7.6 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.8 Clinical Trial Analysis: Distribution by Study Design
Figure 7.9 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Figure 7.10 Clinical Trial Analysis: Distribution by Type of Sponsor
Figure 7.11 Most Active Industry Players: Analysis by Number of Trials
Figure 7.12 Most Active Non-Industry Players: Analysis by Number of Trials
Figure 7.13 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Figure 7.14 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Figure 8.1 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of KOL
Figure 8.2 Allogeneic Cell Therapies KOL Analysis: Distribution by Qualification
Figure 8.3 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 8.4 Allogeneic Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 8.5 Allogeneic Cell Therapies KOL Analysis: Distribution by Target Disease Indication
Figure 8.6 Allogeneic Cell Therapies KOL Analysis: Distribution by Geographical Location of KOLs
Figure 8.7 Most Prominent KOLs: Peer Group 1 (Principal Investigators)
Figure 8.8 Most Prominent KOLs: Peer Group 2 (Study Directors)
Figure 8.9 Most Prominent KOLs: Peer Group 3 (Study Chair)
Figure 8.10 Most Prominent KOLs: Distribution by RA score
Figure 8.11 Most Prominent KOLs: Comparison of RA Score and Third-Party Score
Figure 9.1 Global Allogeneic Cell Therapy Market, 2023-2035 (USD Billion)
Figure 9.2 Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035 (USD Billion)
Figure 9.3 Allogeneic Cell Therapy Market for T-Cell Therapies, 2023-2035 (USD Billion)
Figure 9.4 Allogeneic Cell Therapy Market for Regulatory T-Cell, 2023-2035 (USD Billion)
Figure 9.5 Allogeneic Cell Therapy Market for Stem Cell, 2023-2035 (USD Billion)
Figure 9.6 Allogeneic Cell Therapy Market for Virus-Specific T-Cell, 2023-2035 (USD Billion)
Figure 9.7 Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035 (USD Billion)
Figure 9.8 Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies, 2023-2035 (USD Billion)
Figure 9.9 Allogeneic Cell Therapy Market for Bone Marrow-derived Therapies, 2023-2035 (USD Billion)
Figure 9.10 Allogeneic Cell Therapy Market for Umbilical Cord Blood-derived Therapies, 2023-2035 (USD Billion)
Figure 9.11 Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies, 2023-2035 (USD Billion)
Figure 9.12 Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035 (USD Billion)
Figure 9.13 Allogeneic Cell Therapy Market for Bone Disorder, 2023-2035 (USD Billion)
Figure 9.14 Allogeneic Cell Therapy Market for Critical Limb Ischemia, 2023-2035 (USD Billion)
Figure 9.15 Allogeneic Cell Therapy Market for Crohn’s Disease 2023-2035 (USD Billion)
Figure 9.16 Allogeneic Cell Therapy Market for Diabetic Foot Ulcer, 2023-2035 (USD Billion)
Figure 9.17 Allogeneic Cell Therapy Market for Graft versus Host Disease 2023-2035 (USD Billion)
Figure 9.18 Allogeneic Cell Therapy Market for Leukemia, 2023-2035 (USD Billion)
Figure 9.19 Allogeneic Cell Therapy Market for Lymphoma, 2023-2035 (USD Billion)
Figure 9.20 Allogeneic Cell Therapy Market for Myelodysplastic Syndrome, 2023-2035 (USD Billion)
Figure 9.21 Allogeneic Cell Therapy Market for Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infectious Disease, 2023-2035 (USD Billion)
Figure 9.22 Allogeneic Cell Therapy Market for Others, 2023-2035 (USD Billion)
Figure 9.23 Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
Figure 9.24 Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders, 2023-2035 (USD Billion)
Figure 9.25 Allogeneic Cell Therapy Market for Musculoskeletal Disorders 2023-2035 (USD Billion)
Figure 9.26 Allogeneic Cell Therapy Market for Neurological Disorders, 2023-2035 (USD Billion)
Figure 9.27 Allogeneic Cell Therapy Market for Oncological Disorders, 2023-2035 (USD Billion)
Figure 9.28 Allogeneic Cell Therapy Market for Post- Transplant Infection, 2023-2035 (USD Billion)
Figure 9.29 Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Billion)
Figure 9.30 Allogeneic Cell Therapy Market in North America, 2023-2035 (USD Billion)
Figure 9.31 Allogeneic Cell Therapy Market in the US, 2023-2035 (USD Billion)
Figure 9.32 Allogeneic Cell Therapy Market in Canada, 2023-2035 (USD Billion)
Figure 9.33 Allogeneic Cell Therapy Market in Europe, 2023-2035 (USD Billion)
Figure 9.34 Allogeneic Cell Therapy Market in Germany, 2023-2035 (USD Billion)
Figure 9.35 Allogeneic Cell Therapy Market in the UK, 2023-2035 (USD Billion)
Figure 9.36 Allogeneic Cell Therapy Market in France, 2023-2035 (USD Billion)
Figure 9.37 Allogeneic Cell Therapy Market in Italy, 2023-2035 (USD Billion)
Figure 9.38 Allogeneic Cell Therapy Market in Spain, 2023-2035 (USD Billion)
Figure 9.39 Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Billion)
Figure 9.40 Allogeneic Cell Therapy Market in China, 2023-2035 (USD Billion)
Figure 9.41 Allogeneic Cell Therapy Market in Australia, 2023-2035 (USD Billion)
Figure 9.42 Allogeneic Cell Therapy Market in Japan, 2023-2035 (USD Billion)
Figure 9.43 AB-205 / E-CEL cells (Angiocrine Bioscience): Sales Forecast, till 2035 (USD Billion)
Figure 9.44 allo-APZ2-OTS (RHEACELL): Sales Forecast, till 2035 (USD Billion)
Figure 9.45 ALLO-ASC-DFU (Anterogen): Sales Forecast, till 2035 (USD Billion)
Figure 9.46 CAP-1002 (Capricor Therapeutics): Sales Forecast, till 2035 (USD Billion)
Figure 9.47 CARTISTEM® (Medipost, Hyundai Bioland): Sales Forecast, till 2035 (USD Billion)
Figure 9.48 Cx601 (Tigenix, Takeda): Sales Forecast, till 2035 (USD Billion)
Figure 9.49 CYP-004 (Cynata Therapeutics): Sales Forecast, till 2035 (USD Billion)
Figure 9.50 Cytovir CMV T cells (Kuur Therapeutics): Sales Forecast, till 2035 (USD Billion)
Figure 9.51 Darvadstrocel / Cx601 (Takeda): Sales Forecast, till 2035 (USD Billion)
Figure 9.52 ELIXCYTE (UnicoCell Biomed): Sales Forecast, till 2035 (USD Billion)
Figure 9.53 Grafix® (Osiris Therapeutics): Sales Forecast, till 2035 (USD Billion)
Figure 9.54 iCell CTL (Shanghai iCELL Biotechnology): Sales Forecast, till 2035 (USD Billion)
Figure 9.55 MDR-101 (Medeor Therapeutics): Sales Forecast, till 2035 (USD Billion)
Figure 9.56 MPC-06-ID / Rexlemestrocel-L (Mesoblast, Quintiles): Sales Forecast, till 2035 (USD Billion)
Figure 9.57 MPC-25-Osteo (Mesoblast): Sales Forecast, till 2035 (USD Billion)
Figure 9.58 MultiStem® (Athersys, Medpace): Sales Forecast, till 2035 (USD Billion)
Figure 9.59 NiCord® / Omidubicel (Gamida Cell): Sales Forecast, till 2035 (USD Billion)
Figure 9.60 Orca-T (Orca Bio): Sales Forecast, till 2035 (USD Billion)
Figure 9.61 Osteocel® Plus (NuVasive): Sales Forecast, till 2035 (USD Billion)
Figure 9.62 PLX-PAD (Pluristem Therapeutics): Sales Forecast, till 2035 (USD Billion)
Figure 9.63 Revascor / MPC-150-IM / Rexlemestrocel-L (Mesoblast): Sales Forecast, till 2035 (USD Billion)
Figure 9.64 Stempeucel® (Stempeutics Research): Sales Forecast, till 2035 (USD Billion)
Figure 9.65 Tab-cel® / tabelecleucel / ATA129 / EBV-CTL (Atara Biotherapeutics): Sales Forecast, till 2035 (USD Billion)
Figure 9.66 TEMCELL® HS (JCR Pharmaceutical, Mesoblast): Sales Forecast, till 2035 (USD Billion)
Figure 9.67 Trinity ELITE (Orthofix): Sales Forecast, till 2035 (USD Billion)
Figure 9.68 Trinity Evolution (Orthofix): Sales Forecast, till 2035 (USD Billion)
Figure 9.69 Viralym-M / ALVR105 / Posoleucel (AlloVir): Sales Forecast, till 2035 (USD Billion)

List Of Tables
Table 4.1 List of Allogeneic Cell Therapies
Table 4.2 List of Allogeneic Cell Therapies Developers
Table 5.1 Allogeneic Cell Therapies: List of Partnerships and Collaborations, 2019-2023
Table 6.1 Allogeneic Cell Therapies: List of Funding and Investments, 2019-2023
Table 7.1. Allogeneic Cell Therapies: List of Clinical Trials, 2019-2023
Table 8.1. Allogeneic Cell Therapies: List of Key Opinion Leaders (KOLs)
Table 9.1 Allogeneic Cell Therapies: List of Forecasted Therapies
Table 9.2 AB-205 / E-CEL cells (Angiocrine Bioscience): Net Present Value (USD Billion)
Table 9.3 AB-205 / E-CEL cells (Angiocrine Bioscience): Value Creation Analysis (USD Billion)
Table 9.4 allo-APZ2-OTS(RHEACELL): Net Present Value (USD Billion)
Table 9.5 allo-APZ2-OTS (RHEACELL): Value Creation Analysis (USD Billion)
Table 9.6 ALLO-ASC-DFU (Anterogen): Net Present Value (USD Billion)
Table 9.7 ALLO-ASC-DFU (Anterogen): Value Creation Analysis (USD Billion)
Table 9.8 CAP-1002 (Capricor Therapeutics): Net Present Value (USD Billion)
Table 9.9 CAP-1002 (Capricor Therapeutics): Value Creation Analysis (USD Billion)
Table 9.10 CARTISTEM® (Medipost, Hyundai Bioland): Net Present Value (USD Billion)
Table 9.11 CARTISTEM® (Medipost, Hyundai Bioland): Value Creation Analysis (USD Billion)
Table 9.12 Cx601 (Takeda, Tigenix): Net Present Value (USD Billion)
Table 9.13 Cx601 (Takeda, Tigenix): Value Creation Analysis (USD Billion)
Table 9.14 CYP-004 (Cynata Therapeutics): Net Present Value (USD Billion)
Table 9.15 CYP-004 (Cynata Therapeutics): Value Creation Analysis (USD Billion)
Table 9.16 Cytovir CMV T cells (Kuur Therapeutics): Net Present Value (USD Billion)
Table 9.17 Cytovir CMV T cells (Kuur Therapeutics): Value Creation Analysis (USD Billion)
Table 9.18 Darvadstrocel / Cx601 (Takeda): Net Present Value (USD Billion)
Table 9.19 Darvadstrocel / Cx601 (Takeda): Value Creation Analysis (USD Billion)
Table 9.20 ELIXCYTE (UnicoCell Biomed): Net Present Value (USD Billion)
Table 9.21 ELIXCYTE (UnicoCell Biomed): Value Creation Analysis (USD Billion)
Table 9.22 Grafix® (Osiris Therapeutics): Net Present Value (USD Billion)
Table 9.21 Grafix® (Osiris Therapeutics): Value Creation Analysis (USD Billion)
Table 9.22 iCell CTL (Shanghai iCELL Biotechnology): Net Present Value (USD Billion)
Table 9.23 iCell CTL (Shanghai iCELL Biotechnology): Value Creation Analysis (USD Billion)
Table 9.24 MDR-101 (Medeor Therapeutics): Net Present Value (USD Billion)
Table 9.25 MDR-101 (Medeor Therapeutics): Value Creation Analysis (USD Billion)
Table 9.26 MPC-06-ID / Rexlemestrocel-L (Mesoblast, Quintiles): Net Present Value (USD Billion)
Table 9.27 MPC-06-ID / Rexlemestrocel-L (Mesoblast, Quintiles): Value Creation Analysis (USD Billion)
Table 9.28 MPC-25-Osteo (Mesoblast): Net Present Value (USD Billion)
Table 9.29 MPC-25-Osteo (Mesoblast): Value Creation Analysis (USD Billion)
Table 9.30 MultiStem® (Athersys, Medpace): Net Present Value (USD Billion)
Table 9.31 MultiStem® (Athersys, Medpace): Value Creation Analysis (USD Billion)
Table 9.32 NiCord® / Omidubicel (Gamida Cell): Net Present Value (USD Billion)
Table 9.33 NiCord® / Omidubicel (Gamida Cell): Value Creation Analysis (USD Billion)
Table 9.34 Orca-T (Orca Bio): Net Present Value (USD Billion)
Table 9.35 Orca-T (Orca Bio): Value Creation Analysis (USD Billion)
Table 9.36 Osteocel® Plus (NuVasive): Net Present Value (USD Billion)
Table 9.37 Osteocel® Plus (NuVasive): Value Creation Analysis (USD Billion)
Table 9.38 PLX-PAD (Pluristem Therapeutics): Net Present Value (USD Billion)
Table 9.39 PLX-PAD (Pluristem Therapeutics): Value Creation Analysis (USD Billion)
Table 9.40 Revascor / MPC-150-IM / Rexlemestrocel-L (Mesoblast): Net Present Value (USD Billion)
Table 9.41 Revascor / MPC-150-IM / Rexlemestrocel-L (Mesoblast): Value Creation Analysis (USD Billion)
Table 9.42 Stempeucel® (Stempeutics Research): Net Present Value (USD Billion)
Table 9.43 Stempeucel® (Stempeutics Research): Value Creation Analysis (USD Billion)
Table 9.44 Tab-cel® / tabelecleucel (Atara Biotherapeutics): Net Present Value (USD Billion)
Table 9.45 Tab-cel® / tabelecleucel (Atara Biotherapeutics): Value Creation Analysis (USD Billion)
Table 9.46 TEMCELL® HS (JCR Pharmaceutical, Mesoblast): Net Present Value (USD Billion)
Table 9.47 TEMCELL® HS (JCR Pharmaceutical, Mesoblast): Value Creation Analysis (USD Billion)
Table 9.48 Trinity ELITE (Orthofix): Net Present Value (USD Billion)
Table 9.49 Trinity ELITE (Orthofix): Value Creation Analysis (USD Billion)
Table 9.50 Trinity Evolution (Orthofix): Net Present Value (USD Billion)
Table 9.51 Trinity Evolution (Orthofix): Value Creation Analysis (USD Billion)
Table 9.52 Viralym-M / Posoleucel (Allovir): Net Present Value (USD Billion)
Table 9.53 Viralym-M / Posoleucel (Allovir): Value Creation Analysis (USD Billion)
Table 11.1 Market Landscape: Distribution by Phase of Development
Table 11.2 Market Landscape: Distribution by Route of Administration
Table 11.3 Market Landscape: Distribution by Type of Cell Therapy
Table 11.4 Market Landscape: Distribution by Source of Cell
Table 11.5 Market Landscape: Distribution by Dosing Frequency
Table 11.6 Market Landscape: Distribution by Type of Therapy
Table 11.7 Market Landscape: Distribution by Target Patient Segment
Table 11.8 Market Landscape: Distribution by Target Indication
Table 11.9 Market Landscape: Distribution by Therapeutic Area
Table 11.10 Market Landscape: Distribution by Year of Establishment
Table 11.11 Market Landscape: Distribution by Company Size
Table 11.12 Market Landscape: Distribution by Location of Headquarters
Table 11.13 Market Landscape: Distribution by Number of Therapies
Table 11.14 Partnerships and Collaborations: Distribution by Year of Partnership, 2019-2023
Table 11.15 Partnerships and Collaborations: Distribution by Type of Partnership
Table 11.16 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 11.17 Partnerships and Collaborations: Distribution by Type of Cell Therapy
Table 11.18 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 11.19 Partnerships and Collaborations: Distribution by Type of Partner
Table 11.20 Most Active Players: Distribution by Number of Partnerships
Table 11.21 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 11.22 Partnerships and Collaborations: Local and International Deals
Table 11.23 Funding and Investments: Distribution by Year of Investment, 2019-2023
Table 11.24 Funding and Investments: Distribution by Amount Invested (USD Million)
Table 11.25 Funding and Investments: Distribution by Type of Funding
Table 11.26 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 11.27 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding (USD Million)
Table 11.28 Funding and Investments: Distribution by Type of Investor
Table 11.29 Funding and Investments: Distribution by Type of Therapy
Table 11.30 Funding and Investments: Distribution by Geography (Region-wise)
Table 11.31 Funding and Investments: Distribution by Geography (Country-wise)
Table 11.32 Leading Investors: Distribution by Number of Instances
Table 11.33 Most Active Players: Distribution by Number of Instances
Table 11.34 Most Active Players: Distribution by Amount Invested (USD Million)
Table 11.35 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2023
Table 11.36 Clinical Trial Analysis: Distribution by Trial Status
Table 11.37 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 11.38 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
Table 11.39 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
Table 11.40 Clinical Trial Analysis: Distribution by Trial Phase
Table 11.41 Clinical Trial Analysis: Distribution by Study Design
Table 11.42 Clinical Trial Analysis: Distribution by Trial Status, Trial Phase and Geography
Table 11.43 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 11.44 Most Active Industry Players: Analysis by Number of Trials
Table 11.45 Most Active Non-Industry Players: Analysis by Number of Trials
Table 11.46 Clinical Trial Analysis: Distribution by Geography and Trial Status (Number of Trials)
Table 11.47 Clinical Trial Analysis: Distribution by Geography and Trial Status (Patients Enrolled)
Table 11.48 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of KOL
Table 11.49 Allogeneic Cell Therapies KOL Analysis: Distribution by Qualification
Table 11.50 Allogeneic Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 11.51 Allogeneic Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 11.52 Allogeneic Cell Therapies KOL Analysis: Distribution by Target Disease Indication
Table 11.53 Allogeneic Cell Therapies KOL Analysis: Distribution by Geographical Location of KOLs
Table 11.54 Most Prominent KOLs: Distribution by RA score
Table 11.55 Most Prominent KOLs: Comparison of RA Score and Third-Party Score
Table 11.56 Global Allogeneic Cell Therapy Market: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 11.57 Allogeneic Cell Therapy Market: Distribution by Type of Cell Therapy, 2023 and 2035 (USD Million)
Table 11.58 Allogeneic Cell Therapy Market for Regulatory T-Cell: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.59 Allogeneic Cell Therapies Market for Stem Cell: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.60 Allogeneic Cell Therapy Market for Virus-Specific T-Cell: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.61 Allogeneic Cell Therapy Market: Distribution by Source of Cell, 2023 and 2035 (USD Billion)
Table 11.62 Allogeneic Cell Therapy Market for Peripheral Blood-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.63 Allogeneic Cell Therapy Market for Bone Marrow-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.64 Allogeneic Cell Therapy Market for Umbilical Cord Blood-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.65 Allogeneic Cell Therapy Market for Adipose Tissue-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.66 Allogeneic Cell Therapy Market for Placenta-derived Therapies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.67 Allogeneic Cell Therapy Market: Distribution by Target Indication, 2023 and 2035 (USD Billion)
Table 11.68 Allogeneic Cell Therapy Market for Bone Disorder: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.69 Allogeneic Cell Therapy Market for Critical Limb Ischemia: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.70 Allogeneic Cell Therapy Market for Crohn’s Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.71 Allogeneic Cell Therapy Market for Diabetic Foot Ulcer: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.72 Allogeneic Cell Therapy Market for Graft versus Host Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.73 Allogeneic Cell Therapy Market for Leukemia: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.74 Allogeneic Cell Therapy Market for Lymphoma: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.75 Allogeneic Cell Therapy Market for Myelodysplastic Syndrome: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.76 Allogeneic Cell Therapy Market for Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infectious Disease: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.77 Allogeneic Cell Therapy Market for Others: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion
Table 11.78 Allogeneic Cell Therapy Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
Table 11.79 Allogeneic Cell Therapy Market for Autoimmune / Inflammatory Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.80 Allogeneic Cell Therapy Market for Musculoskeletal Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.81 Allogeneic Cell Therapy Market for Neurological Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.82 Allogeneic Cell Therapy Market for Oncological Disorders: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.83 Allogeneic Cell Therapy Market for Post Transplant Infection: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.84 Allogeneic Cell Therapy Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Billion)
Table 11.85 Allogeneic Cell Therapy Market in North America: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.86 Allogeneic Cell Therapy Market in the US: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.87 Allogeneic Cell Therapy Market in Canada: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.88 Allogeneic Cell Therapy Market in Europe: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.89 Allogeneic Cell Therapy Market in Germany: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.90 Allogeneic Cell Therapy Market in the UK: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.91 Allogeneic Cell Therapy Market in France: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.92 Allogeneic Cell Therapy Market in Italy: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.93 Allogeneic Cell Therapy Market in Spain: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.94 Allogeneic Cell Therapy Market in Asia-Pacific and Rest of the World: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.95 Allogeneic Cell Therapy Market in China: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.96 Allogeneic Cell Therapy Market in Australia: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.97 Allogeneic Cell Therapy Market in Japan: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.98 AB-205 / E-CEL cells (Angiocrine Bioscience): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.99 allo-APZ2-OTS (RHEACELL): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.100 ALLO-ASC-DFU (Anterogen): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.101 CAP-1002 (Capricor Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.102 CARTISTEM® (Medipost, Hyundai Bioland): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.103 Cx601 (Tigenix, Takeda): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.104 CYP-004 (Cynata Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.105 Cytovir CMV T cells (Kuur Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.106 Darvadstrocel / Cx601 (Takeda): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.107 ELIXCYTE (UnicoCell Biomed): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.108 Grafix® (Osiris Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.109 iCell CTL (Shanghai iCELL Biotechnology): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.110 MDR-101 (Medeor Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.111 MPC-06-ID / Rexlemestrocel-L (Mesoblast, Quintiles): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.112 MPC-25-Osteo (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.113 MultiStem® (Athersys, Medpace): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.114 NiCord® / Omidubicel (Gamida Cell): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.115 Orca-T (Orca Bio): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.116 Osteocel® Plus (NuVasive): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.117 PLX-PAD (Pluristem Therapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.118 Revascor / MPC-150-IM / Rexlemestrocel-L (Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 11.119 Stempeucel® (Stempeutics Research): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.120 Tab-cel® / tabelecleucel (Atara Biotherapeutics): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.121 TEMCELL® HS (JCR Pharmaceutical, Mesoblast): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.122 Trinity ELITE (Orthofix): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.123 Trinity Evolution (Orthofix): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)
Table 11.124 Viralym-M / Posoleucel (AlloVir): Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2035 (USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 920th Hospital of Joint Logistics Support Force
  • AbbVie
  • Academisch Medisch Centrum
  • Acepodia 
  • Adaptimmune Therapeutics
  • Adicet Bio
  • Aegle Therapeutics
  • Affiliated Hospital to Academy of Military Medical Sciences
  • Affimed
  • Alaunos Therapeutics 
  • Allogene Therapeutics
  • AlloVir 
  • Alpha Biopharma
  • Altaco XXI
  • Amgen
  • Angiocrine Bioscience
  • Anhui Provincial Hospital
  • Ann & Robert H. Lurie Children's Hospital of Chicago
  • Anterogen
  • Antion Biosciences
  • APICES
  • Athersys
  • Artiva Biotherapeutics 
  • Astellas Pharma 
  • Atara Biotherapeutics 
  • Athenex
  • Athersys
  • Autolomous
  • Azidus Brasil
  • Bayer
  • Baylor College of Medicine 
  • Baylx
  • Be The Match BioTherapies
  • Beijing 302 Hospital
  • Beijing Doing Biomedical
  • Beijing GD Initiative Cell Therapy Technology
  • Beijing Immunochina Medical Science & Technology 
  • JD Biotech
  • Beijing SH biotechnology
  • Beth Israel Deaconess Medical Center
  • BHI Therapeutic Sciences
  • BioCardia
  • Bioceltech Therapeutics
  • BioCentriq
  • Biomedical Advanced Research and Development Authority (BARDA)
  • Biorasi
  • Bioray Laboratories 
  • BioSenic (Previously known as Bone Therapeutics)
  • Bristol Myers Squibb
  • California Institute for Regenerative Medicine
  • Cancer Research UK
  • Capricor Therapeutics 
  • CardioCell
  • Caribou Biosciences
  • Cartesian Therapeutics
  • Junta de Castilla y León
  • Catalent Pharma Solutions 
  • Catamaran Bio
  • Cedars-Sinai Medical Center
  • Celixir
  • Cell2Cure 
  • Cellavita 
  • Cell and Gene Therapy Catapult
  • Cellectis
  • Cellenkos
  • Cellerant Therapeutics
  • Cellerix
  • Celltex Therapeutics
  • Cellular Biomedicine Group (CBMG)
  • Celularity
  • Celyad Oncology
  • Center for Breakthrough Medicines
  • Central South University
  • Centre Hospitalier Universitaire de Limoges
  • Chabiotech
  • Chandler Regional Medical Center
  • Changhai Hospital
  • Huaxia Intech (Biotech) Biotechnology (Previously known as China Immunotech Biotechnology)
  • China-Japan Friendship Hospital 
  • Chinese Academy of Medical Sciences
  • Chinese PLA General Hospital
  • Cipla
  • Citospin
  • Cleveland Clinic
  • Cliniques universitaires Saint-Luc
  • CoImmune
  • Copenhagen University Hospital
  • Corestem
  • CRISPR Therapeutics
  • Cynata Therapeutics
  • CytoMed Therapeutics
  • Cytopeutics 
  • Cytora
  • Cytovia Therapeutics
  • Daewoong Pharmaceutical
  • Department of Health and Human Services 
  • Deverra Therapeutics
  • Direct Biologics
  • DiscGenics
  • Dt&SanoMedics
  • Duke University
  • EdiGene
  • Editas Medicine
  • ElevateBio
  • ENCell
  • Enlivex Therapeutics 
  • European Commission
  • European Union
  • Ever Supreme Bio Technology
  • Fate Therapeutics 
  • Ferrer Internacional
  • FGK Clinical Research
  • FibroBiologics
  • Fondazione Matilde Tettamanti Menotti De Marchi Onlus
  • Formula Pharmaceuticals
  • Fortress Biotech 
  • Fred Hutchinson Cancer Center
  • Fresno Community Hospital and  Medical Center
  • FUJIFILM Diosynth Biotechnologies
  • Fundamenta Therapeutics
  • Gamida Cell
  • GC Cell
  • Gemeinsamer Bundesausschuss
  • Genentech
  • GentiBio
  • Genzyme
  • Ghent University
  • Global Cord Blood Corporation
  • Glycostem Therapeutics
  • Gracell Biotechnologies 
  • Granzer Regulatory Consulting & Services
  • Greenlight Clinical
  • Gwo xi Stem Cell
  • GX Acquisition
  • Qihan Biotech 
  • Hanyang University Medical Center
  • HCW Biologics
  • Hebei Yanda Ludaopei Hospital
  • Help Therapeutics
  • Henan Cancer Hospital
  • Histocell
  • Hope Biosciences 
  • Hospital Clínico Universitario de Valladolid
  • Hospital del Río Hortega
  • Hospital for Special Surgery
  • Hospital Infantil Universitario Niño Jesús
  • Hospital San Carlos
  • Hospital Vera Cruz
  • Huashan Hospital
  • Hyundai Bioland
  • iCAR Bio Therapeutics
  • iCell Gene Therapeutics
  • ICON plc 
  • Infectious Disease Research Institute (IDRI)
  • IMAC Regeneration Centers
  • Immunitybio
  • Implant Therapeutics
  • Imugene
  • IN8bio 
  • Incyte
  • inno.N
  • Innovate UK
  • Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
  • Institute of Hematology & Blood Diseases Hospital
  • Instituto de Salud Carlos III
  • International Research Institute Servier
  • Janssen
  • JCR Pharmaceutical
  • jCyte
  • Jiangsu Topcel-KH Pharmaceutical
  • Jinling Hospital 
  • JW Therapeutics
  • Kadimastem
  • Kangstem Biotech
  • Karolinska Institutet
  • Kinesiometrics
  • KSQ Therapeutics 
  • Kuur Therapeutics 
  • Kyocera
  • Legend Biotech 
  • LG Chem
  • Lineage Cell Therapeutics 
  • Link Health  
  • Longeveron
  • Lonza 
  • LUMICKS
  • Lung Biotechnology PBC
  • M.D. Anderson Cancer Center
  • Magellan Stem Cells
  • Magenta Therapeutics
  • Masonic Cancer Center
  • MaxCyte
  • Mayo Clinic
  • McGill University Health Centre
  • Medac
  • Medeor Therapeutics
  • Medical University of South Carolina
  • MEDIPOST
  • Medpace
  • Medsenic
  • Memorial Sloan Kettering Cancer Center
  • Mendus
  • Merck Sharp & Dohme 
  • Mercy Gilbert Medical Center
  • Mesoblast
  • Ministerio de Ciencia e Innovacion
  • Ministry of Health & Welfare (MOHW)
  • Nanfang Hospital of Southern Medical University
  • Nanjing Bioheng Biotech
  • Nanjing Enricnk Biotech
  • NantKwest
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Health Research and Development (NIHRD) (Indonesia)
  • National University Hospital, Singapore
  • Nature Cell 
  • Neurona Therapeutics
  • NexImmune
  • NextCell Pharma
  • Nippon Shinyaku
  • Nkarta Therapeutics
  • Nohla Therapeutics
  • Northern Therapeutics
  • Novartis Pharmaceuticals
  • NuVasive
  • Ohio State University Comprehensive Cancer Center
  • OmniaBio
  • Oncternal Therapeutics
  • Ono Pharmaceutical
  • Orca Bio
  • Orthofix
  • Osiris Therapeutics
  • Ossium Health
  • Overland Pharmaceuticals
  • Pandorum International
  • PersonGen BioTherapeutics (Suzhou)
  • Pfizer
  • Pharmicell
  • Phio Pharmaceuticals
  • Pieris Pharmaceuticals
  • Pierre Fabre
  • Pluristem Therapeutics
  • Poseida Therapeutics
  • PPD
  • Precision BioSciences
  • Precision Biotech 
  • Pregene
  • ProMab Biotechnologies
  • Promethera Biosciences
  • Protech Pharmaservices
  • PT Prodia StemCell Indonesia (ProSTEM)
  • Pulthera
  • Q Therapeutics
  • Quintiles
  • R3 Stem Cell
  • Red de Terapia Celular
  • Regeneus
  • ReNeuron 
  • Renji Hospital
  • Renmin Hospital of Wuhan University
  • Restem 
  • resTORbio
  • RHEACELL
  • Rigenerand
  • Rigshospitalet
  • Roche
  • Royal Brompton and Harefield hospitals
  • Ruijin Hospital
  • S.Biomedics
  • Salvat
  • Sanofi
  • Santen Pharmaceutical
  • Sclnow Biotechnology 
  • SCM Lifescience
  • Second Affiliated Hospital of Xi'an Jiaotong University
  • Sentien Biotechnologies
  • Seoul CRO
  • Servier
  • Shanghai Changzheng Hospital
  • Shanghai East Hospital
  • Shanghai GeneChem
  • Shanghai General Hospital
  • Shanghai iCELL Biotechnology
  • Shanghai Jiao Tong University School of Medicine
  • Shanghai Ninth People's Hospital 
  • Shanghai Public Health Clinical Center
  • Shanghai Sixth People's Hospital
  • Shenzhen Pregene Biopharma 
  • Shenzhen University General Hospital
  • Shire
  • SK Bioland
  • SMT Bio
  • Sorrento Therapeutics
  • Springworks
  • Staburo
  • Stanford University
  • Stemedica Cell Technologies
  • Steminent Biotherapeutics
  • Stempeutics Research
  • Taiga Biotechnologies
  • Taipei Veterans General Hospital
  • Taiwan Bio Therapeutics
  • Talaris Therapeutics
  • Tang-Du Hospital
  • TC BioPharm
  • Teijin Pharma
  • Tel Aviv Sourasky Medical Center
  • Tessa Therapeutics 
  • Tevogen Bio
  • The Affiliated Hospital of Guizhou Medical University
  • The Affiliated Hospital of Xuzhou Medical University
  • The Affiliated Union Hospital of Fujian Medical University
  • The Cleveland Clinic
  • The First Affiliated Hospital of Anhui Medical University
  • The First Affiliated Hospital of Henan University of Science and Technology
  • The First Affiliated Hospital of Kunming Medical College
  • The First Affiliated Hospital of Soochow University
  • The First Affiliated Hospital of University of Science and Technology of China 
  • The First Affiliated Hospital of Zhengzhou University
  • The First People's Hospital of Hefei
  • The Foundation for Orthopaedics and Regenerative Medicine
  • The General Hospital of Western Theater Command
  • The Marcus Foundation
  • The Methodist Hospital Research Institute
  • The Netherlands Organisation for Health Research and Development
  • The Second Affiliated Hospital of Chongqing Medical University
  • The Second Hospital of Shandong University
  • The University of Texas Health Science Center
  • The University of Texas MD Anderson Cancer Center
  • Thomas Jefferson University
  • TICEBA
  • TiGenix (Acquired by Takeda)
  • Timmune Biotech
  • Tiziana Life Sciences
  • Translational Biosciences
  • Trinity College Dublin
  • Tri-Service General Hospital
  • Triumvira Immunologics
  • Tscan Therapeutics
  • Twist Bioscience
  • UCI Medical Center
  • UMC Utrecht
  • UnicoCell Biomed
  • Universitätsklinikum Hamburg-Eppendorf
  • Universiti Kebangsaan Malaysia Medical Centre
  • Universiti Tunku Abdul Rahman
  • University Medical Center Groningen
  • University of California
  • University of Florida
  • University of Kansas Medical Center
  • University of Louisville
  • University of Miami
  • University of Minnesota
  • University of Munich
  • University of Sydney
  • University of Valladolid
  • University of Wisconsin-Madison
  • Uppsala University
  • National Cancer Institute
  • Utooth Biological Technology
  • VetStem Biopharma
  • ViaCyte
  • ViGenCell
  • Vinmec Research Institute of Stem Cell and Gene Technology
  • Vinnova
  • Virginia Contract Research Organization
  • Viscofan 
  • Vitro Biopharma
  • Washington University
  • Wugen
  • Wuhan Jinyintan Hospital
  • Xindu (A subsidiary of Xintela)
  • Xinqiao Hospital of Chongqing
  • Xintela
  • Xuzhou Medical University
  • Zelluna Immunotherapy
  • Zhejiang University
  • Zhengzhou University

Methodology

 

 

Loading
LOADING...